Dapu Biotechnology

Explore the latest insights on Dapu Biotechnology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Dapu Biotechnology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

TYK Medicines’ Asandeutertinib (TY‑9591) Set to Ship First Commercial Batch – Qilu Pharmaceutical to Launch China Sales of the NMPA‑Approved EGFR‑TKI

TYK Medicines (HKG: 2410) announced that its independently developed new drug, asandeutertinib (TY‑9591), is set to complete production, with the first batch expected to be officially shipped via commercial channels…

November 12, 2026

Abbisko’s PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor

November 12, 2026

Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL

November 12, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Deals

VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation

November 27, 2024

Dapu Biotechnology

TYK Medicines’ Asandeutertinib (TY‑9591) Set to Ship First Commercial Batch – Qilu Pharmaceutical to Launch China Sales of the NMPA‑Approved EGFR‑TKI

Abbisko’s PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor

Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL

Empowering Chinese Pharma’s Global Expansion

VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation

About Company